Resumen

BARRETO-RODRIGUEZ, José O.; MEJIA, Mayra E.  y  BUENDIA-ROLDAN, Ivette. Current prospect of idiopathic pulmonary fibrosis in Mexico. Neumol. cir. torax [online]. 2015, vol.74, n.4, pp.256-261. ISSN 0028-3746.

IPF is a disease characterized by progressive and irreversible pulmonary fibrosis of unknown etiology, incidence and prevalence in the world is highly variable; in Mexico we have no representative epidemiological data. An inquiry was conducted of 419 pulmonologists, of which 168 responded pulmonologists around the country. On average each pulmonologist diagnosed 8 patients with IPF annually. Reference centers that recognize are INER 27%, 6% CMN IMSS, HGM 2%, 2% CEPREP, and 63% denied having reference center. For the diagnostic approach 89% has HRCT and 11% do not have it, 37% is support of an expert radiologist, 31% of an expert pathologist and 63% do not have these specialists. Regarding the initial treatment prescribed prednisone 85%, 46% n-acetilcisteine, 39% azatioprine. Colchicine 12% and 8% pirfenidone. With the results of this study we can conclude that Mexico needs not only train experts pulmonologists in interstitial diseases, it is also essential to increase the number of radiologists and expert pathologists in the subject and form an adequate network of national reference for obtain reliable epidemiological data.

Palabras llave : Idiopathic pulmonary fibrosis; Mexico; inquiry.

        · resumen en Español     · texto en Español     · Español ( pdf )